Embed this press release by copying the code below:

<a class="rwp-pr" href="http://rwire.com/406673">Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail</a><script>!function(){var e="rwp-platform";if(!document.getElementById(e)){var t=document.createElement("script");t.id=e,t.src=("https:"===document.location.protocol?"https":"http")+"://publisher.releasewire.com/embed.js",t.async=!0,document.body.appendChild(t)}}();</script>

Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail